Search Results - "Beraldi, Eliana"

Refine Results
  1. 1
  2. 2

    Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer by SHIOTA, Masaki, BISHOP, Jennifer L, GLEAVE, Martin, ZOUBEIDI, Amina, MUN NIP, Ka, ZARDAN, Anousheh, TAKEUCHI, Ario, CORDONNIER, Thomas, BERALDI, Eliana, BAZOV, Jenny, FAZLI, Ladan, CHI, Kim

    Published in Cancer research (Chicago, Ill.) (15-05-2013)
    “…Defining the mechanisms underlying metastatic progression of prostate cancer may lead to insights into how to decrease morbidity and mortality in this disease…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release by Schmitt, Veronika, Kesch, Claudia, Jackson, John K., Bidnur, Samir, Beraldi, Eliana, Yago, Virginia, Bowden, Mary, Gleave, Martin E.

    Published in Pharmaceutical research (01-03-2020)
    “…Purpose We describe the preparation of injectable polymeric paste (IPP) formulations for local and sustained release of drugs. Furthermore, we include the…”
    Get full text
    Journal Article
  6. 6

    Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity by ZOUBEIDI, Amina, ZARDAN, Anousheh, BERALDI, Eliana, FAZLI, Ladan, SOWERY, Richard, RENNIE, Paul, NELSON, Colleen, GLEAVE, Martin

    Published in Cancer research (Chicago, Ill.) (01-11-2007)
    “…Androgen receptor (AR) transactivation is known to enhance prostate cancer cell survival. However, the precise effectors by which the prosurvival effects of…”
    Get full text
    Journal Article
  7. 7

    Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability by MATSUMOTO, Hiroaki, YAMAMOTO, Yoshiaki, SHIOTA, Masaki, KURUMA, Hidetoshi, BERALDI, Eliana, MATSUYAMA, Hideyasu, ZOUBEIDI, Amina, GLEAVE, Martin

    Published in Cancer research (Chicago, Ill.) (15-08-2013)
    “…Although androgen receptor (AR) pathway inhibitors prolong survival in castrate-resistant prostate cancer (CRPC), resistance rapidly develops and is often…”
    Get full text
    Journal Article
  8. 8

    Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells by Kamada, Masayuki, So, Alan, Muramaki, Mototsugu, Rocchi, Palma, Beraldi, Eliana, Gleave, Martin

    Published in Molecular cancer therapeutics (01-01-2007)
    “…Heat shock protein 27 (Hsp27) is a cytoprotective chaperone that is phosphoactivated during cell stress that prevents aggregation and/or regulate activity and…”
    Get full text
    Journal Article
  9. 9

    Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate Cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD by ZOUBEIDI, Amina, ZARDAN, Anousheh, WIEDMANN, Romina M, LOCKE, Jennifer, BERALDI, Eliana, FAZLI, Ladan, GLEAVE, Martin E

    Published in Cancer research (Chicago, Ill.) (15-03-2010)
    “…Hsp27 is highly expressed in castrate-resistant prostate cancer. Although its overexpression confers resistance to androgen ablation and chemotherapy, the…”
    Get full text
    Journal Article
  10. 10

    Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer by LAMOUREUX, Francois, THOMAS, Christian, YIN, Min-Jean, KURUMA, Hidetoshi, BERALDI, Eliana, FAZLI, Ladan, ZOUBEIDI, Amina, GLEAVE, Martin E

    Published in Cancer research (Chicago, Ill.) (01-09-2011)
    “…Small-molecule inhibitors of Hsp90 show promise in the treatment of castrate-resistant prostate cancer (CRPC); however, these inhibitors trigger a heat shock…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer by ROCCHI, Palma, SO, Alan, KOJIMA, Satoko, SIGNAEVSKY, Maxim, BERALDI, Eliana, FAZLI, Ladan, HURTADO-COLL, Antonio, YAMANAKA, Kazuki, GLEAVE, Martin

    Published in Cancer research (Chicago, Ill.) (15-09-2004)
    “…Heat shock protein 27 (Hsp27) is a chaperone implicated as an independent predictor of clinical outcome in prostate cancer. Our aim was to characterize changes…”
    Get full text
    Journal Article
  13. 13
  14. 14

    A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma by Kesch, Claudia, Schmitt, Veronika, Bidnur, Samir, Thi, Marisa, Beraldi, Eliana, Moskalev, Igor, Yago, Virginia, Bowden, Mary, Adomat, Hans, Fazli, Ladan, Jackson, John K., Gleave, Martin E.

    Published in Urologic oncology (01-03-2021)
    “…•We developed a novel mucoadhesive, polymeric paste formulation of gemcitabine (ST-UC), that can be locally administered via direct instillation to the upper…”
    Get full text
    Journal Article
  15. 15

    Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer by Kumano, Masafumi, Furukawa, Junya, Shiota, Masaki, Zardan, Anousheh, Zhang, Fan, Beraldi, Eliana, Wiedmann, Romina M, Fazli, Ladan, Zoubeidi, Amina, Gleave, Martin E

    Published in Molecular cancer therapeutics (01-08-2012)
    “…Hsp27 is a stress-activated multifunctional chaperone that inhibits treatment-induced apoptosis and causes treatment resistance in prostate and other cancers…”
    Get full text
    Journal Article
  16. 16

    Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis by Al Nakouzi, Nader, Wang, Chris Kedong, Beraldi, Eliana, Jager, Wolfgang, Ettinger, Susan, Fazli, Ladan, Nappi, Lucia, Bishop, Jennifer, Zhang, Fan, Chauchereau, Anne, Loriot, Yohann, Gleave, Martin

    Published in EMBO molecular medicine (01-07-2016)
    “…Clusterin (CLU) is a stress‐activated molecular chaperone that confers treatment resistance to taxanes when highly expressed. While CLU inhibition potentiates…”
    Get full text
    Journal Article
  17. 17

    A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor by Xia, Yi, Wang, Menghua, Beraldi, Eliana, Cong, Mei, Zoubeidi, Amina, Gleave, Martin, Peng, Ling

    Published in Anti-cancer agents in medicinal chemistry (01-01-2015)
    “…A novel triazole nucleoside analogue was discovered to exhibit potent anticancer activity in prostate cancer cells via down-regulating heat shock factor 1…”
    Get more information
    Journal Article
  18. 18

    A polymeric paste-drug formulation for intratumoral treatment of prostate cancer by Kesch, Claudia, Schmitt, Veronika, Bidnur, Samir, Thi, Marisa, Beraldi, Eliana, Moskalev, Igor, Yago, Virginia, Bowden, Mary, Adomat, Hans, Fazil, Ladan, Jackson, John K., Gleave, Martin E.

    Published in Prostate cancer and prostatic diseases (01-06-2020)
    “…Objective Focal therapy has emerged as a treatment option for low- to intermediate-risk localized prostate cancer (PCa) patients, to balance the risks for…”
    Get full text
    Journal Article
  19. 19

    Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer by Shiota, Masaki, Zoubeidi, Amina, Kumano, Masafumi, Beraldi, Eliana, Naito, Seiji, Nelson, Colleen C, Sorensen, Poul H B, Gleave, Martin E

    Published in Molecular cancer research (01-12-2011)
    “…Clusterin is a stress-activated, cytoprotective chaperone that confers broad-spectrum treatment resistance in cancer. However, the molecular mechanisms…”
    Get full text
    Journal Article
  20. 20

    Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo by Thomas, Christian, Zoubeidi, Amina, Kuruma, Hidetoshi, Fazli, Ladan, Lamoureux, Francois, Beraldi, Eliana, Monia, Brett P, MacLeod, A Robert, Thüroff, Joachim W, Gleave, Martin E

    Published in Molecular cancer therapeutics (01-02-2011)
    “…Signal transducer and activator of transcription 5 (Stat5) plays an important role in the transition of prostate cancer (PCa) to its castrate-resistant state…”
    Get full text
    Journal Article